



Planegg/Munich, Germany, April 24, 2017

## **MorphoSys to Host Q1 2017 Conference Call on May 3, 2017**

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months' 2017 results on May 3, 2017 at 7:00 am CEST.

At 3:00 pm CEST (2:00 pm BST, 9:00 am EDT), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's first quarter interim statement 2017 and provide further details on the Company's latest developments.

### **Dial-in numbers (listen only):**

**Germany:** +49 89 2444 32975

**United Kingdom:** +44 20 3003 2666

**USA:** +1 202 204 1514

We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's website at [www.morphosys.com/conference-calls](http://www.morphosys.com/conference-calls)

A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.

The Annual General Meeting of MorphoSys AG will take place on May 17, 2017 in Munich. A live webcast of the event and all related information are available on [www.morphosys.com/agm](http://www.morphosys.com/agm).

### About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic [pipeline](#) of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit <http://www.morphosys.com>.

HuCAL<sup>®</sup>, HuCAL GOLD<sup>®</sup>, HuCAL PLATINUM<sup>®</sup>, CysDisplay<sup>®</sup>, RapMAT<sup>®</sup>, arYla<sup>®</sup>, Ylanthia<sup>®</sup>, 100 billion high potentials<sup>®</sup>, Slonomics<sup>®</sup>, Lanthio Pharma<sup>®</sup> and LanthioPep<sup>®</sup> are registered trademarks of the MorphoSys Group.

*This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.*

**For more information, please contact:**

**MorphoSys AG**

Anke Linnartz

Head of Corporate Communications & IR

Jochen Orłowski

Associate Director Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

**Tel: +49 (0) 89 / 899 27-404**

**[investors@morphosys.com](mailto:investors@morphosys.com)**